Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Surveillance immunitaire et retrait CNI chez les receveurs à faible risque d'une greffe de rein

Surveillance immunitaire et retrait des inhibiteurs de la calcineurine (CNI) chez les receveurs à faible risque d'une greffe de rein

The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.

Aperçu de l'étude

Description détaillée

Kidney transplantation is a treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients take immunosuppression (anti-rejection) drugs to prevent their body from rejecting the new kidney. These drugs are used to prevent the immune system from attacking the transplanted kidney. All anti-rejection medications have unwanted side effects. The purpose of this study is to evaluate the safety of slowly removing tacrolimus, a CNI.

Type d'étude

Interventionnel

Inscription (Réel)

52

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Manitoba
      • Winnipeg, Manitoba, Canada, R3A IR9
        • Health Sciences Centre
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M1
        • Toronto General Hospital
    • California
      • Los Angeles, California, États-Unis, 90055
        • University of California Los Angeles
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06520-8029
        • Yale University School of Medicine
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Brigham & Women's Hospital
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • University of Michigan Hospital
    • Missouri
      • St Louis, Missouri, États-Unis, 63110
        • Washington University
    • New York
      • New York, New York, États-Unis, 10029
        • Mount Sinai School of Medicine
    • Ohio
      • Cleveland, Ohio, États-Unis, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, États-Unis, 44106-5048
        • University Hospitals of Cleveland
    • Texas
      • Houston, Texas, États-Unis, 77030
        • The Methodist Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

INCLUSION CRITERIA -

Initial Enrollment/Screening: Patients who meet all of the following criteria are eligible for enrollment as study subjects:

  • Subject must be able to understand and provide written informed consent;
  • Primary living-donor (related or unrelated) kidney transplant recipients;
  • Peak flow-based PRAs for class I and class II <30%(performed by local center);
  • Current (within 8 weeks prior to transplantation) flow-based PRAs for class I and class II <30% (performed by local center);
  • No donor specific antibody by flow solid phase method on the peak PRA serum (if serum available), or on the current PRA serum (within 8 weeks prior to transplantation) performed by central core laboratory. If the sera for the peak PRA is not available, then only the current PRA serum will be tested;
  • Negative T-cell and B-cell crossmatch by flow cytometry (performed by local center);
  • Female subjects of childbearing potential must have a negative pregnancy test (urine or serum) upon study entry;
  • Female and male subjects with reproductive potential must agree to use FDA approved methods of birth control while participating in the study.

Inclusion Criteria for Randomization:

Participants who meet all of the following criteria are eligible for randomization:

  • No history of acute rejection episodes;
  • The pre-randomization protocol biopsy should confirm no rejection, including borderline rejection (based on the central pathology read);
  • No donor specific antibody as detected by flow solid phase method (performed by the central core laboratory).

EXCLUSION CRITERIA -

Initial Enrollment/Screening:

Participants who meet any of these criteria are not eligible for enrollment as study subjects:

  • Recipient of multiple organ transplants;
  • Prior history of organ transplantation;
  • Deceased-donor source;
  • Any condition that would preclude protocol biopsies;
  • HLA identical recipients;
  • Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
  • Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
  • Inability or unwillingness to comply with study protocol;
  • Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
  • Recent recipient of any licensed or investigational live attenuated vaccine(s) within two months of prior to study entry.

Exclusion Criteria for Randomization:

Participants who meet any of these criteria are not eligible for randomization:

  • Subjects who receive less than 4.5mg/kg of Rabbit ATG (Thymoglobulin®) induction therapy;
  • Subjects who test positive for BKV by PCR in the blood at 6 months post-transplant;
  • Any condition that would preclude protocol biopsies;
  • Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
  • Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
  • Inability or unwillingness of a subject to give written informed consent or comply with study protocol;
  • Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
  • Subjects who receive less than 1500 mg daily of Mycophenolate Mofetil (CellCept®) or equivalent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Tacrolimus (CNI) Withdrawal

Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.

Autres noms:
  • Thymoglobuline®
  • mycophénolate mofétil
  • CellCept®
  • Induction ATG, tacrolimus (CNI), MMF et prednisone, suivi du retrait du CNI
  • globuline antithymocyte de lapin (RATG)
  • inhibiteur de la calcineurine (CNI)

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Autres noms:
  • Thymoglobuline®
  • mycophénolate mofétil
  • CellCept®
  • globuline antithymocyte de lapin (RATG)
  • inhibiteur de la calcineurine (CNI)
  • Induction ATG, Tacrolimus (CNI), MMF et Prednisone
Comparateur actif: Standard Immunosuppressive Therapy

Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Autres noms:
  • Thymoglobuline®
  • mycophénolate mofétil
  • CellCept®
  • globuline antithymocyte de lapin (RATG)
  • inhibiteur de la calcineurine (CNI)
  • Induction ATG, Tacrolimus (CNI), MMF et Prednisone

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of Participants With Incremental IF/A Scores >2 at 24 Months Post-Randomization
Délai: IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.

The investigators were not able to assess this outcome, the effect of the intervention on interstitial fibrosis/tubular atrophy (IF/TA; on a 2-year graft biopsy) due to the study's premature termination by the Data Safety Monitoring Board (DSMB) because of absence of equipoise on the basis of predetermined stopping rules.

IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Estimated GFR Using the Chronic Kidney Disease Epidemiology (CKD-EPI) Equation
Délai: 6 months post-transplantation, 24 months post-transplantation

Estimated glomerular filtration rate (eGFR) is a test to measure the level of kidney function. In this measure, the effects of tacrolimus withdrawal on long-term kidney function was assessed by comparing absolute 24 month eGFR (18 months post-randomization) and change in eGFR from 6 to 24 months (randomization to 18 months randomization). Lower numbers indicate poorer kidney function

6 months post-transplantation, 24 months post-transplantation
Incidence of Acute Rejection
Délai: 6 to 18 months post-randomization

Acute renal allograft rejection is defined as histological reading of borderline or greater determined by the local pathology laboratory. Participants suspected of having a rejection episode on the basis of clinical signs, symptoms, or on the basis of laboratory tests, had a renal ultrasound and underwent a renal transplant biopsy. Any detection of acute cellular rejection or acute humoral rejection resulted in participants in the 'Randomized to Tacrolimus Withdrawal' group to be restarted on tacrolimus and followed per the reduced follow-up schedule of events.

6 to 18 months post-randomization
Allograft Survival Rate
Délai: 6 to 18 months post-randomization

Allograft survival is defined as participants who did not need to be re-transplanted or placed on dialysis due to the failure of their allograft transplantation during the course of this study.

6 to 18 months post-randomization
Participant Survival Rate
Délai: 6 to 18 months post-transplantation

Number of participants who did not die within the course of this study.

6 to 18 months post-transplantation
Percentage of Participants With New Donor Specific Antibodies (DSAs)
Délai: 6 to 18 months post-randomization

Donor specific antibodies are antibodies that are directed against antigens expressed on donor organs. These antibodies can result in an immune attack on the transplanted organ, increasing risk of graft loss and/or rejection.

6 to 18 months post-randomization
Percentage of Participants With Donor-Specific Memory Using Elispot
Délai: 6 to 18 months post-randomization

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 to 18 months post-randomization
Percentage of Participants in the Experimental Arm Off Tacrolimus
Délai: 18 months post-randomization

Participants in the 'Randomized to Tacrolimus Withdrawal' group were considered fully withdrawn once they no longer received any doses of tacrolimus. Participants met this endpoint if they did not resume taking tacrolimus as of 18 months post randomization with stable allograft function and without rejection of donor-specific antibodies.

18 months post-randomization
Incremental Change in IF/TA Scores
Délai: 6 to 18 months post-transplant

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 to 18 months post-transplant
Measurement of Urinary Parameters Before and After Randomization
Délai: 6 months post-transplantation to 18 months post-randomization

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 months post-transplantation to 18 months post-randomization

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: Donald Hricik, MD, University Hospitals Cleveland Medical Center
  • Chercheur principal: Peter S. Heeger, MD, Icahn School of Medicine at Mount Sinai

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 novembre 2010

Achèvement primaire (Réel)

1 mai 2015

Achèvement de l'étude (Réel)

1 mai 2015

Dates d'inscription aux études

Première soumission

20 janvier 2012

Première soumission répondant aux critères de contrôle qualité

20 janvier 2012

Première publication (Estimé)

25 janvier 2012

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

24 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner